Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib in Refractory Metastatic Renal Cell Carcinoma
NCT01253668Phase 2Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Nov 2011
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brivanib alaninate in metastatic renal cell carcinoma (mRCC), sponsored by Abramson Cancer Center. Started Nov 2011; status: terminated.
02
Drugs
brivanib alaninate
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01253668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253668.